Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts

L. I. Valentin, G. A. Sicard, Michael Freeman, B. T. Allen, M. A. McGoff, C. B. Anderson

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Arachidonic acid (AA) and adenosine diphosphate (ADP) are potent stimuli of platelet aggregation. Each agonist may act through separate platelet pathways. In order to evaluate inhibition of ADP and AA on platelet aggregation, we studied the effect of ticlopidine (TC) and aspirin (ASA) alone and in combination on plasma thromboxane levels, platelet deposition, and patency of small-diameter vascular grafts in a canine model. Thirty-four mongrel dogs were classified as thrombosis prone (TP) or thrombosis resistant (TR) on the basis of in vitro platelet aggregation to AA. Four groups were studied: group I, control; group II, TC (100 mg/kg/day); group III, ASA (3 mg/kg/day); and group IV, TC/ASA (same doses). PTFE grafts were implanted bilaterally in the carotid and femoral arteries. Ticlopidine inhibited in vitro platelet aggregation to both ADP and AA but had no significant effect on plasma thromboxane (Tx)B2 production. Aspirin inhibited AA-induced platelet aggregation and significantly decreased TxB2 levels in both TP and TR animals (p < 0.01). Although TC and ASA significantly inhibited platelet deposition and improved 1-month patency in both TP and TR animals, maximal patency was achieved in the group in which TC and ASA were combined. We conclude that platelet ADP and AA pathways are important determinants of the thrombogenic potential in vascular graft performance in dogs and that combined inhibition of both pathways achieves maximal vascular graft patency.

Original languageEnglish (US)
Pages (from-to)178-184
Number of pages7
JournalSurgery
Volume104
Issue number2
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Ticlopidine
Arachidonic Acid
Adenosine Diphosphate
Blood Vessels
Platelet Aggregation
Thrombosis
Blood Platelets
Transplants
Aspirin
Vascular Patency
Dogs
Thromboxane B2
Thromboxanes
Polytetrafluoroethylene
Femoral Artery
Carotid Arteries
Canidae
Control Groups

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Valentin, L. I., Sicard, G. A., Freeman, M., Allen, B. T., McGoff, M. A., & Anderson, C. B. (1988). Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts. Surgery, 104(2), 178-184.

Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts. / Valentin, L. I.; Sicard, G. A.; Freeman, Michael; Allen, B. T.; McGoff, M. A.; Anderson, C. B.

In: Surgery, Vol. 104, No. 2, 01.01.1988, p. 178-184.

Research output: Contribution to journalArticle

Valentin, LI, Sicard, GA, Freeman, M, Allen, BT, McGoff, MA & Anderson, CB 1988, 'Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts', Surgery, vol. 104, no. 2, pp. 178-184.
Valentin LI, Sicard GA, Freeman M, Allen BT, McGoff MA, Anderson CB. Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts. Surgery. 1988 Jan 1;104(2):178-184.
Valentin, L. I. ; Sicard, G. A. ; Freeman, Michael ; Allen, B. T. ; McGoff, M. A. ; Anderson, C. B. / Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts. In: Surgery. 1988 ; Vol. 104, No. 2. pp. 178-184.
@article{cfb4620e9dbc4cc4b7d746b40dd6eabc,
title = "Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts",
abstract = "Arachidonic acid (AA) and adenosine diphosphate (ADP) are potent stimuli of platelet aggregation. Each agonist may act through separate platelet pathways. In order to evaluate inhibition of ADP and AA on platelet aggregation, we studied the effect of ticlopidine (TC) and aspirin (ASA) alone and in combination on plasma thromboxane levels, platelet deposition, and patency of small-diameter vascular grafts in a canine model. Thirty-four mongrel dogs were classified as thrombosis prone (TP) or thrombosis resistant (TR) on the basis of in vitro platelet aggregation to AA. Four groups were studied: group I, control; group II, TC (100 mg/kg/day); group III, ASA (3 mg/kg/day); and group IV, TC/ASA (same doses). PTFE grafts were implanted bilaterally in the carotid and femoral arteries. Ticlopidine inhibited in vitro platelet aggregation to both ADP and AA but had no significant effect on plasma thromboxane (Tx)B2 production. Aspirin inhibited AA-induced platelet aggregation and significantly decreased TxB2 levels in both TP and TR animals (p < 0.01). Although TC and ASA significantly inhibited platelet deposition and improved 1-month patency in both TP and TR animals, maximal patency was achieved in the group in which TC and ASA were combined. We conclude that platelet ADP and AA pathways are important determinants of the thrombogenic potential in vascular graft performance in dogs and that combined inhibition of both pathways achieves maximal vascular graft patency.",
author = "Valentin, {L. I.} and Sicard, {G. A.} and Michael Freeman and Allen, {B. T.} and McGoff, {M. A.} and Anderson, {C. B.}",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "104",
pages = "178--184",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts

AU - Valentin, L. I.

AU - Sicard, G. A.

AU - Freeman, Michael

AU - Allen, B. T.

AU - McGoff, M. A.

AU - Anderson, C. B.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Arachidonic acid (AA) and adenosine diphosphate (ADP) are potent stimuli of platelet aggregation. Each agonist may act through separate platelet pathways. In order to evaluate inhibition of ADP and AA on platelet aggregation, we studied the effect of ticlopidine (TC) and aspirin (ASA) alone and in combination on plasma thromboxane levels, platelet deposition, and patency of small-diameter vascular grafts in a canine model. Thirty-four mongrel dogs were classified as thrombosis prone (TP) or thrombosis resistant (TR) on the basis of in vitro platelet aggregation to AA. Four groups were studied: group I, control; group II, TC (100 mg/kg/day); group III, ASA (3 mg/kg/day); and group IV, TC/ASA (same doses). PTFE grafts were implanted bilaterally in the carotid and femoral arteries. Ticlopidine inhibited in vitro platelet aggregation to both ADP and AA but had no significant effect on plasma thromboxane (Tx)B2 production. Aspirin inhibited AA-induced platelet aggregation and significantly decreased TxB2 levels in both TP and TR animals (p < 0.01). Although TC and ASA significantly inhibited platelet deposition and improved 1-month patency in both TP and TR animals, maximal patency was achieved in the group in which TC and ASA were combined. We conclude that platelet ADP and AA pathways are important determinants of the thrombogenic potential in vascular graft performance in dogs and that combined inhibition of both pathways achieves maximal vascular graft patency.

AB - Arachidonic acid (AA) and adenosine diphosphate (ADP) are potent stimuli of platelet aggregation. Each agonist may act through separate platelet pathways. In order to evaluate inhibition of ADP and AA on platelet aggregation, we studied the effect of ticlopidine (TC) and aspirin (ASA) alone and in combination on plasma thromboxane levels, platelet deposition, and patency of small-diameter vascular grafts in a canine model. Thirty-four mongrel dogs were classified as thrombosis prone (TP) or thrombosis resistant (TR) on the basis of in vitro platelet aggregation to AA. Four groups were studied: group I, control; group II, TC (100 mg/kg/day); group III, ASA (3 mg/kg/day); and group IV, TC/ASA (same doses). PTFE grafts were implanted bilaterally in the carotid and femoral arteries. Ticlopidine inhibited in vitro platelet aggregation to both ADP and AA but had no significant effect on plasma thromboxane (Tx)B2 production. Aspirin inhibited AA-induced platelet aggregation and significantly decreased TxB2 levels in both TP and TR animals (p < 0.01). Although TC and ASA significantly inhibited platelet deposition and improved 1-month patency in both TP and TR animals, maximal patency was achieved in the group in which TC and ASA were combined. We conclude that platelet ADP and AA pathways are important determinants of the thrombogenic potential in vascular graft performance in dogs and that combined inhibition of both pathways achieves maximal vascular graft patency.

UR - http://www.scopus.com/inward/record.url?scp=0023783887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023783887&partnerID=8YFLogxK

M3 - Article

VL - 104

SP - 178

EP - 184

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -